Clients

Arch Therapeutics, Inc.

Company Snapshot: Arch Therapeutics, Inc.

ARTH
Last Change Volume High Low

Company Overview

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.

Featured Documents

Client News

  1. Sep 20 2017 Arch Therapeutics to Provide Corporate Updates at Upcoming Industry and Investment Conferences
  2. Sep 12 2017 Arch Therapeutics Reports Favorable Results in Repeat Dose Testing of AC5™ for Subchronic Systemic Toxicity
  3. Sep 6 2017 Arch Therapeutics to Provide Corporate Update at the 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017
  4. Jul 25 2017 Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel